Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imofinostat

Next Previous
Drug Profile

Imofinostat

Alternative Names: ABT-301; MPT-0E028; TSY-410

Latest Information Update: 23 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Formosa Pharmaceuticals; Taipei Medical University
  • Developer AnBogen Therapeutics; Formosa Pharmaceuticals; Taipei Medical University
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer
  • Phase I Solid tumours
  • Preclinical Idiopathic pulmonary fibrosis; Pancreatic cancer

Most Recent Events

  • 23 Apr 2026 Pharmacodynamics data from preclinical trial in Colorectal cancer and Pancreatic cancer released by AnBogen Therapeutics
  • 13 Apr 2026 Preclinical trials in Pancreatic cancer in Taiwan (PO), prior to April 2026
  • 24 Nov 2025 Phase-I/II clinical trials in Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Australia (PO) (NCT07244705)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top